Legal & General Group Plc Boosts Vertex Pharmaceuticals Stock Holdings

Institutional investor increases stake in biotech firm by 3.3% in Q3 2025

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Legal & General Group Plc, a major institutional investor, increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% in the third quarter of 2025, according to a recent SEC filing. The firm now owns 1,952,297 shares of the pharmaceutical company's stock, valued at $764,598,000 at the end of the quarter.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases, particularly cystic fibrosis. The increase in ownership by a major institutional investor like Legal & General Group Plc suggests confidence in the company's long-term prospects and pipeline.

The details

According to the SEC filing, Legal & General Group Plc acquired an additional 62,520 shares of Vertex Pharmaceuticals during the third quarter, bringing its total ownership to 1,952,297 shares or 0.77% of the company. Vertex Pharmaceuticals is a Boston-based biotech firm known for its portfolio of CFTR modulators that target the underlying cause of cystic fibrosis.

Legal & General Group Plc filed the SEC disclosure on March 10, 2026.
The increase in Vertex Pharmaceuticals shares occurred during the third quarter of 2025.

The players